Clinical Trial Detail

NCT ID NCT02484404
Title Phase 1 and 2 Study of MEDI4736 in Combination With Olaparib or Cediranib for Advanced Solid Tumors and Recurrent Ovarian Cancer
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

Advanced Solid Tumor

Therapies

Cediranib + Durvalumab

Durvalumab + Olaparib

Age Groups: adult

No variant requirements are available.